"Karolinska Universitetssjukhuset i Solna och Huddinge är ett av Europas största universitetssjukhus. Tillsammans med Karolinska Institutet utgör sjukhuset ett medicinskt centrum med högt internationellt anseende."

During the past decade, Karolinska Universitetssjukhuset - Solna conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 21 clinical trials were completed, i.e. on average, 38.2% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 12 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Karolinska Universitetssjukhuset - Solna" #1 sponsor was "Pfizer" with 8 trials, followed by "Takeda" with 8 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored, "Amgen" with 4 trials sponsored and "Bayer" with 4 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Karolinska Universitetssjukhuset - Solna" #1 collaborator was "Karolinska Institutet" with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Karolinska Universitetssjukhuset - Solna" are "Hemophilia A" (4 trials), "Colitis, Ulcerative" (3 trials), "Prostate Cancer" (3 trials), "Psoriasis" (3 trials) and "Amyotrophic Lateral Sclerosis" (2 trials). Many other conditions were trialed in "Karolinska Universitetssjukhuset - Solna" in a lesser frequency.

Most popular intervention types in "Karolinska Universitetssjukhuset - Solna" are "Drug" (53 trials), "Biological" (12 trials), "Other" (7 trials), "Device" (5 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Enzalutamide" (3 trials), "Niraparib" (3 trials), "Prednisone" (3 trials) and "Capecitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Karolinska Universitetssjukhuset - Solna" are 65 trials for "All" genders, 11 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Karolinska Universitetssjukhuset - Solna". undefined are not yet recruiting, 21 are recruiting, 21 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Karolinska Universitetssjukhuset - Solna, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Karolinska Universitetssjukhuset - Solna, 6 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 12 trials that are defined as “Not Applicable".